it was possible to demonstrate that physiological levels of retinoic acid and epidermal growth factor were capable of preventing the differentiation of these malignant keratinocytes into a mature tissue-like structure. The terminal differentiation caused by certain antineoplastic agents was investigated in HL-60 promyelocytic leukaemia cells to provide information on the mechanism by which chemotherapeutic agents induce cells to by-pass a maturation block. The anthracyclines aclacinomycin A and marcellomycin were potent inhibitors of N-glycosidically linked glycoprotein biosynthesis and transferrin receptor activity, and active inducers of maturation; temporal studies suggested that the biochemical effects were associated with the differentiation process. 6-Thioguanine produced cytotoxicity in parental cells by forming analog nucleotide. In hypoxanthine-guanine phosphoribosyltransferase negative HL-60 cells the 6-thiopurine initiated maturation; this action was due to the free base (and possibly the deoxyribonucleoside), a finding which separated termination of proliferation due to cytotoxicity from that caused by maturation.
Significant advances have been made towards the cure and palliation of cancer with existing chemotherapeutic agents; however, since the mechanism of action of these drugs is dependent upon the cytodestruction of neoplastic cells, their beneficial effects are usually accompanied by significant morbidity. This suggests that approaches to cancer therapy should be sought that do not involve cell kill; one such approach envisions the conversion of malignant cells through induced differentiation to benign forms with no proliferative potential. This approach assumes that malignancy is not an irreversible state, as has been demonstrated with a variety of tumour types, including teratocarcinomas (Pierce & Wallace, 1971; Brinster, 1974) , neuroblastomas (Schubert et al., 1971; Prasad, 1983) squamous cell carcinomas (Pierce & Wallace, 1971) , leukaemias (Metcalf et al., 1969; Paran et al., 1970; Gootwine et al., 1982) , and adenocarcinomas of the breast (Decosse et al., 1973; Pierce et al., 1977) . The use of differentiation as a therapeutic approach also presumes that cancer is a disease of altered maturation. Such a phenomenon can be readily visualized in constantly renewing tissues in which mature cellular elements with a finite life-span are continually being regenerated by an active stem cell compartment. The carcinogenic event may be visualized to interfere with the progression of a developing cell through the maturation pathway, blocking that cell at a stage at which it retains infinite proliferative capability. Under these conditions, an amplification of the altered clone is produced, and progression to more anaplastic forms can occur. In tissues devoid of a stem cell population such as neurons, it is simplest to envision a dedifferentiation caused by the carcinogenic event, which leads to a more primitive cellular form with proliferative capability. Investigations of the role of oncogenes on the blockage of differentiation have demonstrated that in muscle cells certain genes have a direct effect on the expression of a developmental program, whereas others act indirectly to disrupt the regulation of growth, preventing withdrawal of cells from the proliferative pool (Falcone et al., 1985) . The therapeutic objective, in all of these situations, is to push cells by the block in maturation so that they may *Delivered at the 26th Annual Meeting of the British Association for Cancer Research, Birmingham, March 26, 1985. progress to more mature cellular elements with no proliferative capability.
Squamous cell carcinoma as a model of blocked maturation
Evidence is available which suggests that malignant epithelial cells have a decreased capacity to undergo terminal differentiation relative to their normal counterparts (Rheinwald & Beckett, 1980; Yuspa & Morgan, 1981; Parkinson et al., 1983) . Thus, normal murine skin keratinocytes undergo a significant degree of terminal maturation in tissue culture when calcium is present in high concentrations, whereas carcinogen-treated mouse skin cells fail to differentiate as measured by keratinization under similar conditions (Yuspa & Morgan, 1981) . Furthermore, transformed human keratinocytes exhibit a decreased capacity to attain a differentiated state when treated with phorbol-12-myristate 13-acetate (Parkinson et al., 1983) . In an analogous manner, human squamous carcinoma cells of the skin or the head and neck region differentiated much more slowly than normal epithelial cells when artificially deprived of anchorage (Rheinwald & Beckett, 1980) . Elucidation of the mechanisms that regulate the differentiation of malignant epithelial cells compared to their normal counterparts would appear to be important for the development of effective therapeutic approaches that employ differentiation as the strategic tactic in these diseases.
We have used a human cell line (SqCC/Yl) derived from a carcinoma of the stratified squamous epithelium of the cheek as a model to study the regulation of the differentiation of malignant keratinocytes (Reiss et al., 1985; submitted). These cells grow predominantly as a monolayer in culture medium consisting of equal volumes of Dulbecco's modified Eagle's medium and Ham's medium F12 supplemented with 10% heat inactivated foetal bovine serum. Replacement of the serum supplemented medium by one containing insulin, transferrin and selenium in place of the foetal bovine serum, resulted in spontaneous maturation that involved the formation of a stratified structure composed of four to six layers of cells, with a progressive thinning of the cells in layers furthest removed from the surface of the culture plate. Desmosomes were present and cells became elongated and progressively devoid of structure except for tonofilament bundles. Keratinization occurred and the cells attained the capacity to form a cornified cell envelope in a manner that resembled that of the maturation of normal epidermal cells in culture (Holbrook & Hennings, 1983) . Two factors which interfered with the differentiation of SqCC/Yl cells in culture were retinoic acid, at a concentration as low as 10-8 M (Reiss et al., 1985; submitted) and epidermal growth factor (EGF), which inhibited maturation at a level of 0.1 ng ml - (King & Sartorelli, 1985) . Both the retinoids and EGF may well function to regulate normal epithelial cell proliferation and differentiation since both of these agents are capable of interfering with normal keratinocyte maturation in culture (Sun & Green, 1976; Fuchs & Green, 1981; Green & Watt, 1982; Cline & Rice, 1983; Kim et al., 1984; Wille et al., 1984 (1984) , using a relatively large number of malignant epithelial cell lines, have shown that the number of EGF receptors per cell is 3.4-to 54-fold higher in cultured malignant keratinocytes than in normal keratinocytes. Circumvention of the effects of the retinoid block on SqCC/Yl cells can be obtained using hydrocortisone, which appears to be competitive with the retinoids (Reiss et al., 1985a (Friend et al., 1971; Reuben et al., 1980) , hormones (Lotem & Sachs, 1975) , vitamins (Breitman et al., 1980; Takenaga et al., 1980; Abe et al., 1981; Schwartz et al., 1983a) , tumour promoters (Huberman & Callaham, 1979; Lotem & Sachs, 1979) , and several clinically useful cancer chemotherapeutic agents (Lotem & Sachs, 1974; Ebert et al., 1976; Scher & Friend, 1978; Terada et al., 1978; Collins et al., 1980; Papac et al., 1980; Bodner et al., 1981; Gallo et al., 1982; Schwartz & Sartorelli, 1982; Schwartz et al., 1983b; Ishiguro et al., 1984) , promote the differentiation of various cell types in culture. Thus, it is conceivable that some of the antineoplastic agents currently in use may exert their therapeutic effects through a mixture of cytodestructive and differentiation-inducing actions. The anthracyclines represent a class of cancer chemotherapeutic agents with significant potency as inducers of the differentiation of HL-60 leukaemia cells. The more conventional clinically used anthracycline antibiotics such as adriamycin and daunorubicin are inactive as initiators of the maturation of this leukaemia cell line; however, the oligosaccharide-containing anthracyclines, aclacinomycin A and marcellomycin, are potent inducers of differentiation, being active in the nanomolar region (Schwartz & Sartorelli, 1982) . The activity of these latter two agents would appear to be due to the trisaccharide portion of the molecules, since the corresponding monosaccharide anthracycline pyrromycin was at best an exceedingly weak inducer of maturation in this system. Examination of the effects of dimethylsulphoxide and marcellomycin on the growth of HL-60 cells in culture indicated that little replication took place from 5 to 10 days after exposure of cells to these two agents (Schwartz & Sartorelli, 1982) ; these effects appeared to be due to a mixture of cytotoxic and differentiation producing actions by both the polar solvent and the anthracycline.
Virtually all agents which induce the maturation of leukaemia cells in culture express this activity at a concentration slightly below that required to produce cell death. It is important to emphasize that it is exceedingly difficult to separate the phenomenon of termination of proliferation by differentiation from that of cell kill, since terminal differentiation to a mature cell leads to a finite life span. Furthermore, since these cells cannot be expected to achieve complete normalcy, their life span may be relatively short. That HL-60 leukaemia cells treated with anthracyclines undergo a commitment to terminal maturation has been demonstrated in an in vivo clonal assay by our laboratory (Schwartz et al., 1983a) . These studies have demonstrated that HL-60 cells undergo an average of 4 and a maximum of 5 divisions following commitment to undergo granulocytic differentiation when exposed to marcellomycin. They are in agreement with findings using the Friend erythroleukaemia which demonstrate an inducer stimulated transition to a restriction in the self-renewing capabilities of the cells Osborne et al., 1982) .
Aclacinomycin A would appear to be the anthracycline with the most clinical potential since this antibiotic has considerably less myelotoxicity than its counterpart, marcellomycin, and both antibiotics are equiactive as inducers of differentiation. Approximately 40% of patients with previously untreated acute leukaemia have been reported to respond to aclacinomycin with complete remissions (Yamada et al., 1980) . Of considerable interest are reports which indicate that the response rate in patients refractory to chemotherapy or relapsing after receiving drugs, including adriamycin and daunorubicin, was 17 to 30% (Yamata et al., 1980; DeJager et al., 1981; Warrell et al., 1981) . Furthermore, Sakurai et al., (1983) reported the response of a patient with acute myeloblastic leukaemia to aclacinomycin A which was suggestive of a differentiative process.
The anthracycline antibiotics produce a variety of metabolic actions which may be responsible for the initiation of maturation and the subsequent termination of proliferation through the formation of end-stage cells (see for a review, . Many studies have suggested that the anthracyclines exert their cytotoxic effects by virtue of intercalation with DNA (see for example, Painter, 1978) . DuVernay et al. (1979) reported that the length of the oligosaccharide side-chain of the anthracycline was a major determinant in the binding of these agents to DNA. This group also demonstrated that the oligosaccharide-containing anthracyclines, such as marcellomycin and aclacinomycin A, inhibit RNA synthesis in vitro at concentrations which are from 6-to 19-fold lower than those required to inhibit DNA biosynthesis (DuVernay et al., 1978) . In contrast, the monosaccharide-containing anthracyclines, adriamycin, daunorubicin and pyrromycin, inhibit the synthesis of both RNA and DNA at essentially equivalent concentrations. A clear difference exists between the activities of marcellomycin and aclacinomycin and those of adriamycin and pyrromycin with respect to the inhibition of nucleolar RNA synthesis relative to that of DNA synthesis (Crooke et al., 1978) . Furthermore, the former compounds were markedly more potent in terms of the inhibition of nucleolar RNA synthesis than were the latter anthracyclines. Thus, it is conceivable that the capacity to inhibit nucleolar RNA synthesis is related to the ability of marcellomycin and aclacinomycin to act as potent inducers of (Heifetz et al., 1979) , led to the production of phenotypically mature cells. Retinoic acid, which also has the potential to interfere with the formation of lipid-linked oligosaccharide intermediates (Creek et al., 1983) , is also a potent inducer of HL-60 leukaemia cell maturation (Collins et al., 1980) . In addition, a number of investigators (Cossu et al., 1982; Felsted et al., 1983; Skubitz & August, 1983) have demonstrated changes in the expression of cell surface glycoproteins during the induction of differentiation of leukaemia cells. Among the best characterized of these modifications are changes in the expression of the transferrin receptor (TFR), the down regulation of which appears to be involved in the series of programmed events that lead to the termination of proliferation through differentiation to mature cellular forms. Thus, when a variety of leukaemia systems (i.e., M-1, K562, or HL-60 cells) are induced to differentiate to more functionally mature cells by a variety of agents, including dexamethasone, dimethylsulphoxide, butyrate, or retinoic acid, the cell surface expression of the transferrin receptor is significantly reduced as an early event (Schulman et al., 1981; Tei et al., 1982; Testa et al., 1982; Yeh et al., 1982; Felsted et al., 1983; Morin & Sartorelli, 1984) .
Furthermore, anti-TFR monoclonal antibodies inhibit the growth of a variety of malignant cell lines Taetle et al., 1983; (Bodner et al., 1981) , tiazofurin and mycophenolic acid (Lucas et al., 1983a; Sokoloski & Sartorelli, 1984) , and xylosyladenine (Garret & Kredich, 1981) have been reported to be effective inducers of the differentiation of the Friend erythroleukaemia and the HL-60 promyelocytic leukaemia. The optimum concentrations of these analogues for the induction of maturation are in the range where they elicit cytotoxicity, suggesting that the mechanisms responsible for both processes are identical. This concept is supported by the finding that xylosyladenine (Garret & Kredich, 1981) and bromodeoxyuridine (Koeffler et al., 1983) are devoid of inducing ability in mutant cell lines with deletions in adenosine kinase and thymidine kinase, respectively. Furthermore, induction of the erythroid differentiation of Friend cells by the aminonucleoside puromycin is inhibited by inosine (Terada et al., 1978) , an antagonist of this analogue nucleoside (Studzinski & Ellem, 1968) . These results collectively support the concept that the activation of these analogues to the nucleotide level not only is essential for cytotoxicity but is also required for the induction of maturation. 6-Thioguanine differs from these agents in that it is an effective initiator of maturation in both Friend and HL-60 leukaemia cells deficient in hypoxanthine-guanine phosphoribosyl transferase (HGPRT) Schwartz et al., 1982; Gallagher et al., 1984; Ishiguro et al., 1984) but at best is only weakly active against parental wild type cells (Papac et al., 1980; Gallagher et al., 1984; Ishiguro et al., 1984) .
Considerable evidence is available to support the concept that 6-thioguanine, like most purines and pyrimidines and their nucleosides, must be converted to the nucleotide level to express cytotoxicity (see for example, Brockman, 1963) . Multiple sites of action have been described for thioguanine nucleotides, including their incorporation into both RNA and DNA (Sartorelli et al., 1958; LePage, 1960; LePage & Jones, 1961; LePage & Howard, 1963; Bieber & Sartorelli, 1964; Kwan et al., 1973; Carrico & Sartorelli, 1977) , and inhibition of glutamine phosphoribosylpyrophosphate amidotransferase (McCollister et al., 1964; Hill & Bennett, 1969) , inosine 5'-phosphate dehydrogenase (Hampton, 1963; Miech et al., 1967) , adenosine triphosphate: guanosine 5'-phosphate phosphotransferase (Miech et al., 1969) and glycoprotein biosynthesis (Lazo et al., 1977; . To identify the metabolic form(s) of 6-thioguanine responsible for the induction of the differentiation of HL-60/HGPRT-cells, intracellular and extracelklar metabolites of thioguanine were analyzed (Ishiguro et al., 1984) . The purine antimetabolite was not appreciably metabolized by these cells, indicating that 6-thioguanine itself was the metabolic form which initiated maturation. The capacity of 6-thioguanosine and 3 -2'-deoxythioguanosine to induce differentiation was also examined. When HL-60/HGPRT-cells were incubated with these nucleosides, large amounts of the nucleosides were converted to 6-thioguanine by purine nucleoside phosphorylase (PNP); the simultaneous exposure of the cells to 6-thioguanosine or fl-2'-deoxythioguanosine and 8-aminoguanosine, an inhibitor of PNP activity, minimized degradation of the nucleosides. Under these conditions, intracellular accumulation of thioguanine nucleotides occurred, presumably through the action of nucleoside kinase activities, and no induction of differentiation was observed. Deoxycytidine kinase (DCK) has been shown to phosphorylate fl-2'-deoxythioguanosine (Nakai & LePage, 1972) . To eliminate the action of DCK, a double mutant of HL-60 cells deficient in both HGPRT and DCK activities was developed. In these cells, ,B-2'-deoxythioguanosine was devoid of cytotoxicity and was an effective inducer of maturation. The potency of deoxythioguanosine as an inducer in this sytem was not prevented by the presence of 8-aminoguanosine, suggesting that deoxythioguanosine itself was also an active initiator of maturation. The findings also suggested that the formation of 6-thioguanine nucleotides serves to antagonize the maturation process in addition to producing cytotoxicity. Furthermore, the studies demonstrate that the metabolic form(s) of the purine antimetabolite which induce differentiation differ from those that produce cytotoxicity, implying that the biochemical events required to arrest growth by these different processes are distinct. In support of this conclusion, differences occurred in the stage of cell cycle arrest produced by 6-thioguanine in parental and HL-60/HGPRTcells (Schwartz et al., 1985) . Wild type HL-60 cells treated with the purine antimetabolite accumulated in the S and G2 + M phases of the cell cycle, a finding similar to that occurring in other cell lines demonstrating toxicity when treated with this agent (Wotring & Roti Roti, 1980) . In contrast, HL-60/HGPRT-cells which terminate proliferation through maturation when treated with 6-thioguanine accumulated in Gi. Arrest of cells in G1 is not unexpected for mature cells (see for example, Prescott, 1976) . In support of this concept, both HL-60 and HL-60/HGPRT-cells respond to dimethylsulphoxide by the initiation of differentiation and an increase in G cells.
Parental HL-60 cells respond to the exposure to 6-thioguanine with cytotoxicity rather than differentiation; this action is due to the fact that the concentration of the purine antimetabolite required to induce maturation in this cell line is significantly higher than that required to produce cytotoxicity. Toxicity of 6-thioguanine to parental cells could be circumvented by exposing thioguanine treated HL-60 cells simultaneously to hypoxanthine or its nucleosides (Ishiguro & Sartorelli, 1985) . Under these conditions, accumulation of 6-thioguanine nucleotides, the cytotoxic form(s) of this agent in HL-60 cells treated with the purine antimetabolite, was markedly decreased by the presence of the physiological purine. This resulted in a marked decrease in the cytotoxic potency of thioguanine, and the differentiation inducing properties of the purine antimetabolite were expressed. Hypoxanthine protects against the cytodestructive properties of thioguanine by preventing the anabolism of the purinethiol to its nucleotide level; this may occur through competition between hypoxanthine and 6-thioguanine at several levels. These include (a) the transport carrier for hypoxanthine/guanine (Plagemann et al., 1981) ; (b) the enzyme HGPRT; and (c) 5-phosphoribosyl 1-pyrophosphate (PRPP), with the activation of hypoxanthine to inosine 5'-phosphate leading to a decreased availability of PRPP for the synthesis of 6-thioguanosine 5'-phosphate by HGPRT. Information of this kind would appear to be critical before an agent such as 6-thioguanine is tested for its capacity to induce maturation in a clinical setting.
Conclusions
A few trials have been conducted to determinc whether the induction of leukaemia cell differcntiation could be attained in a clinical setting (see forappropriate references, Schwartz & Wiernik, 1985) . These investigations suffer from an inability to differentiate between the cytotoxic and maturation producing actions of the agents employed. In addition, considerable additional fundamental information would appear to be required to most efficaciously apply the concepts of differentiation therapy to the treatment of malignant diseases of man. Phenomena such as commitment time, which often requires one to two cell generations of continuous exposure in culture to inducing agent to achieve an irreversible commitment to form endstage mature cells, suggests that continuous infusion of agents under test would be required for this period of time for optimum effects in patients with malignant disease. This possible requirement is sorely in need of evaluation in an animal system. The phenomenon of memory, whereby cells exposed to an inducer of differentiation for less than the period of time required to achieve commitment retain this information for an additional division cycle or more, and undergo a significant degree of differentiation when cells are reexposed to inducer for a relatively short period of time consistent with an appropriate cumulative exposure to that inducer (see for example, Fibach et al., 1979; Murate et al., 1984; Yen et al., 1984; Yen, 1984) 
